Our Management Team
Chief Executive Officer & CO-Founder, KAREN TORREJON, PH.D.
Dr. Karen Torrejon, Co-Founder and CSO, invented the Glauconix platform technology in response to an unmet need in drug discovery/development and looking to bring more effective therapies to patients. Karen worked in drug discovery for 3 years prior to launching Humonix. She was recognized by MIT Technology Review as an Innovator Under 35, the Albany Business review 40 under 40, and has been the recipient of 20+ scientific and technical awards. Dr. Torrejon has a PhD from the State University of New York, College of Nanoscale Science and Engineering, and a BS in Physics & Chemistry from the University at Albany.
CO-FOUNDER & chief TECHNICAL officer, FERYAN AHMED, PH.D.
Dr. Feryan Ahmed, Co-Founder, brings 20+ years of pre-clinical drug development experience to Humonix. Prior to Humonix, he worked as a Senior Scientist at Albany Molecular Research Inc. (now Curia Bio) where he supervised multiple medicinal chemistry and drug discovery projects and managed teams of 10-15 scientists. While at Humonix Dr. Ahmed helped develop a high-throughput perfusion system and optimized the scaffold fabrication technology. Dr. Ahmed has a PhD from the University of Minnesota and a MS from SUNY Polytechnic Institute.
Our Technical Advisors
Barbara Wirostko, MD FARVO
Dr. Barbara Wirostko is the Chief Medical Officer and Co-Founder of Qlaris Bio, as well as an adjunct professor in Ophthalmology and and Biomedical Engineering at John A Moran Eye Center, University of Utah. She has previously worked at EyeGate Pharmaceuticals as the Chief Medical Officer, Jade Pharmaceuticals as the Chief Science Officer, and Pfizer in their Ophthalmology division as a Senior Medical Director.
Robert Ritch, MD
Dr. Ritch is the distinguished chair in Ophthalmology, surgeon and Chief of Glaucoma services at New York Eye and Ear Infirmary of Mount Sinai(NYEE). He also serves as the Chair with the Glaucoma Foundation, and he has devoted his career to innovation in the medical, laser and surgical treatment of glaucoma.
W. Daniel Stamer, PhD FARVO
Dr. Stamer is the President of the Association for Research in Vision and Ophthalmology at Duke University as well as a professor of Ophthalmology at Joseph A.C. Wadsworth. He pioneered Schlemm’s canal cell isolation and manipulation and serves as an advisor to various pharmaceutical companies developing ophthalmic drugs.
John Danias, MD, PhD
Dr. Danias is the Chairman of Ophthalmology at the SUNY Downstate College of Medicine and the Founder of Opthalmic Vision Solution. He has won a Lewis Rudin Award from the NY Academy of Medicine, and is a devoted Glaucoma medical clinician/surgeon and Principal Investigator.
Louis Pasquale, MD FARVO
Dr. Pasquale is the Vice Chair for Research Director of Glaucoma Services at Harvard Medical, Massachusetts Eye and Ear Infirmary. He is also the co-director of Harvard Glaucoma Center of Excellence and has won the Silver Fellow Award, Association for Research in Vision and Ophthalmology.